Oral and parenteral anticoagulants: New kids on the block

Journal of Postgraduate Medicine

Volumn 58, Issue 4, 2012, Pages 275-285

  Aditya, S ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apixaban; dabigatran; novel anticoagulants; rivaroxaban

Indexed keywords

ADOMIPARIN; ANTICOAGULANT AGENT; ANTISENSE OLIGONUCLEOTIDE; APIXABAN; ARGATROBAN; ATECEGATRAN METOXIL; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BMS 2620837; BMS 262084; BMS 593214; CLAVATADINE A; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; EP 21709; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PCI 274836; PEGNIVACOGIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RECOMODULIN; RIVAROXABAN; RO 14; SEMULOPARIN; SOLULIN; TANOGITRAN; TB 402; TECARFARIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; REVIEW; THROMBOCYTE ACTIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FACTOR XA; HUMANS; INFUSIONS, PARENTERAL;

EID: 84873452135     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.105448     Document Type: Review

References (81)

1. Gomez-outes A, Suarez-gea ML, Lecumberri R, Rocha E, Pozo-hernandez C, Vargas-castrillon E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 2011;5:33-59.
2. Heit JA. Estimating the incidence of symptomatic postoperative venous thromboembolism: The importance of perspective. JAMA 2012;307:306-7.
3. Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk and outcomes in elderly patients. Am Heart J 2011;161:241-6.
4. McMillin GA, Vazquez SR, Pendleton RC. Current challenges in personalizing warfarin therapy. Expert Rev Clin Pharmacol 2011;4:349-62.
5. Steffel J, Braunwald E. Novel oral anticoagulants: Focus on stroke prevention and treatment of venous thromboembolism. Eur Heart J 2011;32:1968-76.
6. Font MA, Krupinski J, Arboix A. Antithrombotic medication for cardio embolic stroke prevention. Stroke Res Treat 2011;2011: Article ID 607852. Available from: http://www.downloads.hindawi.com/journals/srt/2011/607852.pdf. [Last cited on 2012 May 4].
7. Avidan MS, Smith JR, Skrupsky IP, Hill L, Jacobsohn E, Burnside B, et al. The occurrence of antibodies to heparin platelet factor 4 in cardiac and thoracic surgical patients receiving desirudin or heparin for postoperative venous thrombosis prophylaxis. Thromb Res 2011;128:524-9.
8. Alkindi S, Smith OP, Enright H. Successful use of alternative anticoagulants in the management of heparin-induced thrombocytopenia with thrombotic complications. Sultan Qaboos Univ Med J 2011;11:391-8.
9. Weitz JI, Eikelboom JW, Samama MM: American College of Chest Physicians. New anti thrombotic drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based clinical practice guidelines. Chest 2012;141:e120S-51S.
10. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010;103:62-70.
11. Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial fibrillation: The potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost 2011;9:441-9.
12. Morales-Vidal S, Schneck MJ, Flaster M, Biller J. Direct thrombin inhibitors and factor Xa inhibitor in patients with cerebrovascular disease. Expert Rev Neurother 2012;12:179-90.
13. Rybak I, Ehle M, Buckley L, Fanikos J. Efficacy and safety of novel anticoagulants compared with established agents. Ther Adv Hematol 2011;2:175-95.
14. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al.: Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012;59:1413-25.
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
16. The Executive Steering Committee on behalf of the ROCKET-AF Study Investigators. Rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET-AF Study. Am Heart J 2010;159:340-7.
17. Granger CB, Alexander JH, Mc Murray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
18. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thrombo-embolism after total knee replacement: The REMODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
19. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
20. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. Thromb Res 2010;126:175-82.
21. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomized, double blind, non-inferiority trial. Lancet 2007;370:949-56.
22. Lassen MR, Ageno W, Borris LC, Lieberman J, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
23. The EINSTEIN Investigators. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
24. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
25. The Einstein PE investigators. Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
26. Kakkar AK, Brenner B, Dahl OE, Erikson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double blind randomized controlled trial. Lancet 2008;372:31-9.
27. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomized trial. Lancet 2009;373:1673-80.
28. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
29. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. The ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement(ADVANCE-2): A randomized double-blind trial. Lancet 2010;375:807-15.
30. Lassen MR, Gallus A, Raskob G, Pineo G, Chen D, Ramirez LM, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement: The ADVANCE 3 trial. N Engl J Med 2010;363:2487-98.
31. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATEII). A randomized, double-blind non inferiority trial. Thromb Haemost 2011;105:721-9.
32. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Sieqbahn A, et al. Dabigatran vs. Placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9.
33. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndrome (ATLAS ACS-TIMI 46): A randomized, doubleblind, phase II trial. Lancet 2009;374:29-38.
34. Syed Y. Modern anticoagulants threaten status quo. Pharmaceutical industry news article. Available from: http://www.pmlive.com/pharma-news/Modern- anticoagulants-threaten-status-quo 411610. [Updated 2012 Aug 6; Last cited on 2012 Aug 21].
35. Mussailidis S, Hardy A. Aptamers as inhibitors of target proteins. Expert. Expert Opin Ther Pat 2009;19:1073-82.
36. Lombo B, Diez JG. Future anticoagulants in interventional cardiology: Anti-IXa and anti Xa agents in percutaneous coronary intervention. Future Cardiol 2011;7:281-5.
37. Muller J, Freitag D, Mayer G, Potzsch B. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 2008;6:2105-12.
38. Fuji T, Fujita S, Tachibana S, Kawai Y. Edoxaban versus enoxaparin for the prevention of venous thromboembolism: Pooled analysis of venous thromboembolism and bleeding from STARS E-3 and STARS J-V. American Society of Hematology 2011 Annual Meeting; December 12, 2011: SanDiego, CA. Abstract 208. Available from: http://www.the heart.org/article/1329499/print.do. [Last cited on 2012 Aug 23].
39. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra R, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNti coaGulation with factor xA next GEneration in atrial fibrillation- thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41.
40. Ezekowitz MD. A phase 2, randomized parallel group, dose finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open label dose adjusted warfarin in patients with non valvular atrial fibrillation (Explore-Xa) Late breaking clinical trial session II. Presented at the American College of Cardiology 59th Annual Scientific sessions, March 2010 Atlanta, GA. Available from: http://www.portola.com/pdfs/Betrixaban-EXPLORE-ACC- 032010.pdf. [Last cited on 2012 May 05].
41. Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101:68-76.
42. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, et al. Otamixaban for the treatment of patients with non-ST elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42), a randomized, double-blind, active controlled, Phase 2 trial. Lancet 2009;374:787-95.
43. The van Gogh Investigators. Extended prophylaxis of venous thromboembolism with Idraparinux. N Engl J Med 2007;357:1105-12.
44. Lane DA, Kamphuisen PW, Minini P, Buller HR, Lip GY. Bleeding risk in patients with atrial fibrillation: The AMADEUS study. Chest 2011;140:146-55.
45. Buller HR, Gallus AS, Pillion G, Prins MH, Raskob GE, Decousus H, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: A randomized, double blind, double dummy, non-inferiority trial. Lancet 2012;379:123-9.
46. The EQUINOX investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011;9:92-9.
47. Lassen MR, Fisher W, Mouret P, Agnelli G, George D, Kakkar A, et al. Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: Results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 AND SAVE-KNEE. J Thromb Haemost 2012;10:822-32.
48. Dehnel T. Semuloparin for thromboprophylaxis during chemotherapy. Lancet Oncol 2012;13:e143. Available from: http://www.thelancet. com/journals/lanonc/ article/PIIS1470-2045(12)70079-7/full text. [Last cited on 2012 May 08].
49. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al.: For SAVE-ONCO investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601-9.
50. Gomez-Outes A, Lecumberri R, Pozo C, Rocha E. New anticoagulants: Focus on venous thromboembolism. Curr Vasc Pharmacol 2009;7:309-29.
51. Kishimoto TK, Qi YW, Long A, Capila I, Sasisekhran R, Guerrero L, et al. M 118-a rationally engineered low molecular weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb Haemost 2009;102:900-6.
52. Henry BL, Thakkar JN, Liang A, Desai UR. Sulfated Low molecular weight lignins inhibit a select group of heparin-binding serine proteases. Biochem Biophys Res Commun 2012;417:382-6.
53. Schumacher WA, Luettgen JM, Quan ML, Seiffert DA. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 2010;30:388-92.
54. Wong PC, Crain EJ, Watson CA, Schumacher WA. A small molecule factor Xia inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis 2011;32:129-37.
55. Zhang H, Lowenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: A novel antithrombotic strategy with lowered bleeding risk. Blood 2010;116:4684-92.
56. Buchanan MS, Carroll AR, Wessling D, Jobling M, Avery VM, Davis RA, et al. Clavatadine A, A natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem 2008;51:3583-7.
57. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy undergoing percutaneous coronary intervention. Circulation 2010;122:614-22.
58. Vavalle JP, Cohen MG. The REG 1 anticoagulation system: A novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol 2012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22420328. [Last cited on 2012 May 4].
59. Sullenger B, Woodruff RD, Monroe DM. Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. J Biol Chem 2012;28:12779-86.
60. Verhamme P, Tangelder M, Verhaeghe R, Ageno W, Glazer S, Prins M, et al. Single intravenous administration of TB 402 for the prophylaxis of venous thromboembolism after total knee replacement: A dose-escalating, randomized, controlled trial. J Thromb Haemost 2011;9:664-71.
61. Sanchez JF, Le L, Arroliga AC. How tifacogin could not captivate severe community acquired pneumonia. Am J Respir Crit Care Med 2011;183:1449-50.
62. Zhao J, Aguilar G, Palencia S, Newton E, Abo A. rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res 2009;15:208-16.
63. Study of safety and tolerability of PCI-27483 on patients with pancreatic cancer patients receiving treatment with gemcitabine. Available from: http://www.clinicaltrials.gov(NCT 01020006). [Last cited on 2012 May 2].
64. Wong PC, Luettgen JM, Rendina AR, Kettner CA, Xin B, Knabb RM, et al. BMS-593214, an active site-directed factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies. Thromb Haemost 2010;104:261-9.
65. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, et al. Thrombomodulin alpha in the treatment of infectious patients complicated by disseminated intravascular coagulation: Sub analysis from phase III trial. Shock 2011;35:349-54.
66. Okamoto T, Tanigami H, Suzuki K, Shimaoka M. Thrombomodulin: A bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract 2012;2012:614545. [10 pages]. Available from: http://www.hindawi.com/ journals/ccrp/2012/614545. [Last cited on 2012 May 04].
67. Petitou M, Nancy-Portebois V, Dubreucq G, Motte V, Meuleman D, de Kort M, et al. From heparin to EP217609: The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009;102:804-10.
68. Olson ST, Swanson R, Petitou M. Specificity and selectivity profile of EP217609: A new neutralizable dual action anticoagulant that targets thrombin and factor Xa. Blood 2012;119:2187-95.
69. Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923) in patients with atrial fibrillation. Circulation 2009;120: 1029-35.
70. Ansell J. Warfarin versus new agents: Interpreting the data. Hematol Am Soc Hematol Educ Program 2010;2010:212-8.
71. Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011;18:349-55.
72. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, et al. Factor XIIa inhibitor recombinant human albumin infestin 4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010;121:1510-7.
73. Vassiliou VS. Apixaban versus warfarin in atrial fibrillation. N Engl J Med 2012;366:88-90.
74. Ansell J. New oral anticoagulants should not be used as first line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012;125:165-70.
75. Moussouttas M. Challenges and controversies in the medical management of primary and anti thrombotic related intracerebral hemorrhage. Ther Adv Neurol Disord 2012;5:43-56.
76. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor with haemostatic agents. Thromb Haemost 2012;107: 253-9.
77. Harenberg J, Marx S, Erdle S, Kramer R. Determination of the anticoagulant effects of new oral anticoagulants: An unmet need. Expert Rev Hematol 2012;5:107-13.
78. Gray RM, Nagendran M, Maruthappu M. Is it safe to stop anticoagulants after successful surgery for atrial fibrillation? Interact CardioVasc Thorac Surg 2011;13:642-9.
79. Altman R, Vidal HO. Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J 2011;9:12. Available from: http://www. thrombosisjournal.com/content/ pdf/1477-9560-912.pdf. [Last cited on 2012 May 05].
80. Schirmer SH, Baumhakel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: Current clinical evidence and future developments. J Am Coll Cardiol 2010;56:2067-76.
81. O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: A review of clinical trials. Clin Ther 2012;34:894-901.